BS

Bhavna Sakwar

Active Director Director DIN 07772382
DIN 07772382 First appointment Jul 2017 Primary industry Business Services
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2017
Shareholding value •••• Premium profile

About Bhavna Sakwar

Data last updated:

Bhavna Sakwar is a Director at Triaim Pharma Private Limited (since 2017). The company operates in Business Services. Triaim Pharma Private Limited reported revenue of ₹93 Lakh (FY 2024).

DIN 07772382
Primary Designation Director
Industry Business Services
First Appointment 20 Jul 2017
Oldest Company Age 9 yrs
Largest company Triaim Pharma Private Limited · ₹93 Lakh (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Triaim Pharma Private Limited U74999MP2017PTC043768
Director20 Jul 20172017₹93 Lakh (FY 2024)Active

Board colleagues of Bhavna Sakwar

Directorship timeline

Open interactive timeline →
Triaim Pharma Private Limited
Premium access

Shareholding and investment profile for Bhavna Sakwar

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Bhavna Sakwar

Bhavna Sakwar currently holds 1 directorship: Triaim Pharma Private Limited (Director, since 20 Jul 2017, revenue ₹93 Lakh (FY 2024)).

Bhavna Sakwar was first appointed on 20 Jul 2017 as Director at Triaim Pharma Private Limited.

The current boards of Bhavna Sakwar's companies include Manisha Shrivas (Triaim Pharma Private Limited), Mohammad Javed (Triaim Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available